DU
ARCT icon

Delphia (USA)’s Arcturus Therapeutics ARCT Stock Holding History

Delphia (USA)’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,287
Closed -$238K – 19
2023
Q2 		$238K Sell
8,287
-7,378
-47% -$201K 0.38% 125
2023
Q1 		$375K Buy
+15,665
New +$281K 0.46% 77

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Delphia (USA)'s ARCT Position: Q3 2023 in Review

Delphia (USA) sold out of Arcturus Therapeutics (ARCT) in Q3 2023, closing a stake of 8,287 shares — an estimated $238K sold.

Delphia (USA) first reported a position in ARCT in Q1 2023 and held it in 2 quarters. The position peaked at $375K in Q1 2023. 145 funds tracked by Wall St. Rank hold ARCT as of Q3 2023.

  • Delphia (USA) reported no remaining Arcturus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 8,287 Arcturus Therapeutics shares in Q3 2023, an estimated $238K.
  • Delphia (USA) first reported a position in Arcturus Therapeutics in Q1 2023 and held it in 2 quarters.
  • Delphia (USA)'s Arcturus Therapeutics position peaked at $375K in Q1 2023.
  • 145 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.